PubMed Health⌕ Search

Biomedical subjects

J Ducobu

Publications and source records attributed to J Ducobu.

78 records · Page 5Linked to original sources
PubMedDate not supplied

[The endocannabinoid system and the regulation of the metabolism].

The endocannabinoid system modulates many physiological functions by acting on receptors CB1 and CB2. The endocannabinoids are produced only when and where they are needed. They act locally and are immediately metabolised after their action. Overactivation of the endocannabinoid system is observed in obesity, with stimulation of the appetite in the hypothalamus and fat accumulation in the adipocytes with increase of insulin resistance and decrease of adiponectin. Nicotine use overactivates also the endocannabinoid system. CB1 blockade by a specific inhibitor (rimonabant) decreases food intake and weight in animal studies and increases adiponectin and insulin sensitivity. Moreover, rimonabant decreases tobacco dependence. Clinical studies with rimonabant are encouraging.

Cannabinoid Receptor Modulators↗
PubMedDate not supplied

[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].

The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus and increase of fat accumulation in adipocytes. The blockade of the cannabinoid system (CB1) by the specific inhibitor (rimonabant) decreases food intake and adiposity in animals and in humans. Moreover rimonabant lowers tobacco addiction. Clinical studies (RIO-LIPIDS and RIO-EUROPE) have recently confirmed that rimonabant combined with a hypocaloric diet over 1 year, promoted significant decrease of body weight, waist circumference and improvement of dyslipidemia. Rimonabant was well tolerated with mild and transient side effects. The future place of rimonabant in the strategy of obesity is still to be clarified.

Animals↗
PubMedDate not supplied

[Chronic hypernatremia. A study of plasma neurophysins and action of morphine].

The hypothalamo-neurohypophyseal function was evaluated in a patient with the chronic hypernatremia syndrome. By dosing plasmatic neurophysins, a selective loss of the osmoreceptor function was demonstrated. Morphine administration was followed by a reduction of the diuresis and a slight elevation of plasmatic neurophysins. The mechanism of morphine action is discussed.

Chronic Disease↗
PubMedDate not supplied

[Hypercholesterolemia: to treat or not to treat? That is the question].

Numerous epidemiological studies have confirmed the positive correlation of elevated serum cholesterol levels to increased coronary risk. Clinical and angiographical trials have shown that modification of hypercholesterolaemia by diet or drugs can lower cardiovascular morbidity and mortality. No good evidence exists that lowering serum cholesterol is harmful. In some meta-analyses enhancing statistical power, total mortality appears to be decreased in primary prevention trials if hypercholesterolaemia is sufficiently reduced. Current guidelines for cholesterol modification should include the primary prevention with identification of individuals at high risk, combined with population information, and the secondary prevention for the patients with symptomatic coronary heart disease.

Age Factors↗